Skip to Main Content

Aimmune Therapeutics, maker of a peanut allergy treatment, said Monday that it will be acquired by the food conglomerate Nestle, which is seeking to expand its health sciences unit.

The all-cash deal values Aimmune at $2.6 billion, or $34.50 per share. Aimmune shares closed Friday at $12.60, near a four-year low due to the company’s struggles to launch its Palforzia peanut allergy treatment during the coronavirus pandemic.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!